BioSpace News Archive

TC Biopharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, is pleased to announce the appointment of 4 new members to its Board of Directors.

Qualigen Therapeutics, Inc. today issues the following Letter to Shareholders:

Cerveau Technologies, Inc. (Cerveau) and Nihon Medi-Physics (NMP), a leading company for radiopharmaceuticals in Japan, today announced that they signed a manufacturing service agreement, in which Cerveau grants NMP the right to manufacture [18F]MK-6240, a next generation investigational Positron Emission Tomography (PET) imaging agent.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical-stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced the start of efficacy animal studies with INTASYL-based antiviral compounds against SARS-CoV-2 infection, the virus that causes COVID-19.

The partnership with PDA, located in Canada, was announced at the Animal Health, Nutrition and Technology Innovation Europe 2022.

Brand Institute is proud to announce its successful partnership with Maxim Biomedical (MaximBio) in naming their MaximBio ClearDetect™ COVID-19 Antigen Home Test.

MRO Corporation (MRO), a leading clinical data acquisition and release platform and the KLAS-rated No. 1 provider of release of information (ROI) solutions, announced today the acquisition of Nashville, TN-based MediCopy, a leading provider of release of information solutions to physician practices and outpatient providers.

NextGen Jane, announced that it has received the green light for the second phase of a Small Business Innovation Research (SBIR) Fast Track grant by the Eunice Kennedy Shriver National Institute of Child Health and Development (NICHD), part of National Institutes of Health (NIH).

Myricx Pharma (‘Myricx’), a drug discovery company focused on developing small molecule inhibitors that selectively target the human.

Arthrosi Therapeutics, Inc., a clinical-stage biotech company developing a new uricosuric agent for the management of hyperuricemia in patients with gout, announced the appointment of Philip Moody as its Chief Financial Officer.